Novartis (NVS) said Monday the European Commission approved Rhapsido for adults with chronic spontaneous urticaria who inadequately respond to traditional antihistamines.

Clinical trials demonstrated symptom improvements by the first week with a favorable safety record and no liver issues, the company said.